Archive for the ‘misconduct investigations’ Category
Immunology paper retracted for inappropriate presentation but “no evidence of intentional misconduct”
However, the original data are now unavailable, according to the notice, so there’s no way to know if the paper’s conclusions are sound.
The Japanese endocrinology researcher Shigeaki Kato, with at least 25 retractions to his name, is alleged to have been the ringleader of a scheme to cover up other research misconduct at the University of Tokyo, his former employer, which investigated the activity.
A researcher who admitted in 2012 to “intentional and systematic manipulation” of data and had two papers retracted has been banned from funding by the German Research Foundation (DFG).
Dennis Rottländer, who will also be returning prize money he was awarded for the research, worked in Uta C. Hoppe’s lab at the University of Cologne. Hoppe, now at University Hospital Salzburg, remains under investigation, according to a statement from the DFG.
Excerpt: Read the rest of this entry »
A Boston doctor indicted on charges of Medicare fraud in 2007 has had a paper relating to the case retracted this month.
Abdul Razzaque Ahmed was considered something of a miracle worker by his patients, treating two rare and disfiguring skin conditions called pemphigoid and pemphigus vulgaris. He used more powerful medicines than the typical course of treatment, including a drug normally used to treat cancer.
The initial indictment stated that Ahmed mixed blood samples to falsely show a “dual diagnosis” of both diseases, and prove to Medicare that they required the more rigorous (and expensive) treatment. It also alleged that he profited massively from the government pay-outs. He was convicted of obstruction in 2007; the other charges were dropped when he agreed to forfeit assets worth $2.9 million.
Now, a 2001 paper by Ahmed, which claimed fifteen patients had a dual diagnosis, has been retracted because the samples were all mixed. Here is the retraction notice from Clinical Immunology: Read the rest of this entry »